Cardiovascular disease is the single biggest killer of lupus patients, accounting for roughly 33% of all deaths. Lupus patients are three times more likely to die from heart and blood vessel disease than people without the condition. But heart disease is only part of the picture. Infections, kidney failure, and the disease itself all claim lives, and the balance between these threats shifts depending on a patient’s age, how long they’ve had the disease, and even the medications used to treat it.
The average age at death for lupus patients has risen from about 48 years in the mid-1990s to around 62 years today, a real improvement driven by better treatments. But that still represents a life cut significantly short, and the causes of death have shifted along with it.
Heart Disease and Accelerated Atherosclerosis
Lupus drives a process of premature atherosclerosis, the buildup of fatty plaques in arteries, through chronic inflammation and immune system attacks on blood vessel walls. This isn’t the slow arterial aging most people experience over decades. In lupus, it happens faster and earlier, which is why heart attacks and strokes strike lupus patients at younger ages than expected.
Traditional risk factors like high cholesterol and high blood pressure don’t fully explain why lupus patients face triple the cardiovascular death rate. The disease itself, specifically the ongoing inflammation and the steroids used to control it, accelerates plaque buildup independently. This means that even a lupus patient who eats well, exercises, and has normal cholesterol is still at significantly elevated risk compared to the general population.
Infections: The Second Major Threat
Lupus attacks the immune system, and so do many of the drugs used to treat it. That double hit leaves patients dangerously vulnerable to infections. Pneumonia is by far the most common serious infection, occurring at roughly five times the rate of other major infections like abdominal infections or a fungal lung infection called Pneumocystis pneumonia.
Two factors dramatically raise infection risk. Kidney damage (which lupus itself causes) nearly triples the likelihood of serious infection. And steroid doses above 15 milligrams per day increase the risk by 3.5 times. Even patients on low steroid doses face significantly higher rates of pneumonia, influenza, shingles, and urinary tract infections compared to patients not taking steroids at all.
One bright spot: hydroxychloroquine, one of the foundational lupus treatments, cuts the risk of serious infection by about 65%. This is one of several reasons doctors push to keep patients on it long-term.
Kidney Failure
About half of all lupus patients develop some degree of kidney inflammation, called lupus nephritis. Among those who do, the numbers are sobering. Roughly 10% reach end-stage kidney failure within five years, and 13% within ten years. Ten-year survival for lupus nephritis patients is 70%, and their overall death rate is six times higher than the general population’s.
Age matters enormously here. Patients diagnosed with lupus nephritis before age 40 face a 12-fold increase in mortality compared to their peers. Those diagnosed after 40 face a four-fold increase. Kidney involvement is the single strongest predictor of a worse outcome in lupus, which is why regular urine and blood tests to monitor kidney function are so critical.
The Disease Itself
In younger patients, particularly those in their late teens and early twenties, lupus itself is the most common cause of death. The disease can cause catastrophic flares that damage multiple organs simultaneously, overwhelming the body before treatments have time to work. As patients age and the disease stabilizes, direct lupus deaths become less common, and cardiovascular disease and infections take over as the leading threats.
This pattern creates a cruel timeline. Early on, the disease is trying to kill you directly. Later, the accumulated organ damage and treatment side effects become the bigger danger. Patients who develop organ damage in their first few years have dramatically worse long-term odds: 25% of those with early organ damage die within 10 years, compared to about 7% of those who avoid it.
How Steroid Treatment Contributes
Steroids remain essential for controlling lupus flares, but long-term use comes with a heavy cost. Patients taking high doses of oral steroids have nearly four times the death rate of patients not on steroids. Even low doses are associated with a 59% increase in mortality risk the following year.
The damage is cumulative. Steroids raise blood pressure, weaken bones (causing osteoporosis and bone death), promote cataracts, cause stomach ulcers, and increase diabetes risk. Every one of these complications showed up at significantly higher rates across all steroid dose levels in a large national study. Immunosuppressant drugs, the other pillar of lupus treatment, carry their own risks: higher rates of shingles, urinary tract infections, and a 54% increase in cancer risk.
This creates a difficult balancing act. Undertreating lupus lets the disease destroy organs. Overtreating it with steroids creates its own path to early death. Modern lupus management increasingly focuses on minimizing steroid exposure while using targeted therapies to control the disease.
Cancer Risk
Lupus patients die from cancer at about 1.5 times the rate of the general population. Lung cancer is the standout, with a death rate 2.5 times higher than expected. Blood cancers also trend higher, though the data is less definitive. Both the disease’s chronic immune activation and the immunosuppressant drugs used to treat it likely contribute to this elevated risk.
Who Faces the Greatest Risk
Lupus does not kill equally. Black patients have the highest death rate at 25%, compared to roughly 14-15% for white, Asian, and Hispanic patients over the same follow-up period. Black patients die an average of nearly 7 years earlier than white patients, and Hispanic patients die 9.5 years earlier than non-Hispanic patients.
When compared to the general population within their own racial group, the picture shifts in a striking way. Hispanic and Latina women with lupus are six times more likely to die than Latina women without it. Asian women with lupus are four times more likely to die than Asian women without it. These disparities reflect differences in disease severity, access to care, socioeconomic factors, and possibly genetic variations in how the disease behaves.
Childhood-onset lupus carries an independent three-fold increase in death risk even after adjusting for age and disease duration. Children who develop lupus tend to have more aggressive kidney involvement and accumulate more organ damage over their longer disease course.
What Improves Survival
Overall survival has improved substantially. For patients diagnosed before age 50, the five-year survival rate is now 99.5% and the ten-year rate is about 98%. For those diagnosed at 50 or older, five-year survival is 95% and ten-year survival is roughly 90%.
The biggest survival gains come from preventing organ damage in the first place. Hydroxychloroquine, started at diagnosis and continued long-term, protects against organ damage accumulation in the first five years and reduces infection risk. Newer biologic therapies have shown the ability to slow and reduce organ damage progression compared to standard treatment alone. Minimizing steroid doses whenever possible removes one of the most significant contributors to long-term complications and death.
Aggressive monitoring for kidney disease, cardiovascular risk management beyond standard guidelines, and prompt treatment of infections all contribute to the improving survival numbers. The gap between a 48-year average age of death in the 1990s and 62 years today reflects real progress, but it also underscores how much ground remains.